166 related articles for article (PubMed ID: 27583930)
21. Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.
Sasaki K; Margonis GA; Andreatos N; Wilson A; Weiss M; Wolfgang C; Sergentanis TN; Polychronidis G; He J; Pawlik TM
Br J Surg; 2017 Jun; 104(7):926-935. PubMed ID: 28266705
[TBL] [Abstract][Full Text] [Related]
22. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
[TBL] [Abstract][Full Text] [Related]
23. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A;
Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481
[TBL] [Abstract][Full Text] [Related]
24. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
25. Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis.
Jácome AA; Oliveira FA; Lino F; Lima JPSN
Clin Colorectal Cancer; 2021 Sep; 20(3):265-272. PubMed ID: 34158251
[TBL] [Abstract][Full Text] [Related]
26. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Kemeny N; Huang Y; Cohen AM; Shi W; Conti JA; Brennan MF; Bertino JR; Turnbull AD; Sullivan D; Stockman J; Blumgart LH; Fong Y
N Engl J Med; 1999 Dec; 341(27):2039-48. PubMed ID: 10615075
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
28. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
[TBL] [Abstract][Full Text] [Related]
29. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E
Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142
[TBL] [Abstract][Full Text] [Related]
31. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
32. Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Kim SA; Kim JW; Suh KJ; Chang W; Kim JW; Oh HK; Cho JY; Kim DW; Cho S; Kim JH; Kim K; Kang SB; Jheon S; Lee KW
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2399-2410. PubMed ID: 32358699
[TBL] [Abstract][Full Text] [Related]
33. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
Wang Y; Yuan YF; Lin HC; Li BK; Wang FH; Wang ZQ; Ding PR; Chen G; Wu XJ; Lu ZH; Pan ZZ; Wan DS; Sun P; Yan SM; Xu RH; Li YH
Chin J Cancer; 2017 Oct; 36(1):78. PubMed ID: 28969708
[TBL] [Abstract][Full Text] [Related]
34. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
[TBL] [Abstract][Full Text] [Related]
35. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review.
Okuno M; Hatano E; Nishino H; Seo S; Taura K; Uemoto S
Eur J Surg Oncol; 2017 Jun; 43(6):1003-1012. PubMed ID: 27624917
[TBL] [Abstract][Full Text] [Related]
36. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Duran AO; Karaca H; Besiroglu M; Bayoglu IV; Menekse S; Yapici HS; Yazilitas D; Bahceci A; Uysal M; Sevinc A; Hacibekiroglu I; Aksoy A; Tanriverdi O; Arpaci E; Inanc M; Dane F; Ozkan M
Asian Pac J Cancer Prev; 2014; 15(23):10375-9. PubMed ID: 25556478
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
[TBL] [Abstract][Full Text] [Related]
38. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
39. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
[TBL] [Abstract][Full Text] [Related]
40. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
Masi G; Salvatore L; Boni L; Loupakis F; Cremolini C; Fornaro L; Schirripa M; Cupini S; Barbara C; Safina V; Granetto C; Fea E; Antonuzzo L; Boni C; Allegrini G; Chiara S; Amoroso D; Bonetti A; Falcone A;
Ann Oncol; 2015 Apr; 26(4):724-730. PubMed ID: 25600568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]